Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study

Buysschaert, Martin; Baeck, Marie; Preumont, Vanessa; Marot, Liliane; Hendrickx, Emilie; Belle, Astrid Van; Dumoutier, Laure

doi:10.1111/bjd.12886

Cited by 57 publications

(68 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, all of the patients studied in the above clinical reports demonstrated weight loss [6][7][8][9][10][11] . However, clinical improvement of psoriasis was achieved prior to any changes in weight [6,[9][10][11] . In a case series of 7 psoriasis patients treated with liraglutide, no correlation was observed between weight loss and PASI [9] .…”

Section: Clinical Reportsmentioning

confidence: 87%

“…However, a case series study showed no correlation between PASI changes and HbA 1c levels [9] . Many reports have shown PASI improvement in patients already possessing good glycemic control [10] .…”

Section: Clinical Reportsmentioning

confidence: 95%

“…Many reports have shown PASI improvement in patients already possessing good glycemic control [10] . Improvement in HbA 1c , a long-term indicator of glycemic control, was seen after 18 weeks of treatment with liraglutide in some of the patients who demonstrated an improved PASI after 7 weeks [9] . Unfortunately, fasting plasma glucose levels were not measured.…”

Section: Clinical Reportsmentioning

confidence: 96%

“…In one study, acitretin for 4 months was ineffective, but improved PASI and Dermatology Life Quality Index were seen after liraglutide had been initiated [8] . Prospective case series studies demonstrated significant improvements in PASI and epidermal thickness within 7 weeks of GLP-1 receptor agonist treatment in comparison to baseline [9,11] .…”

Section: Clinical Reportsmentioning

confidence: 97%

“…However, clinical improvement of psoriasis was achieved prior to any changes in weight [6,[9][10][11] . In a case series of 7 psoriasis patients treated with liraglutide, no correlation was observed between weight loss and PASI [9] . Therefore, although it is plausible that GLP-1 receptor agonists may improve psoriasis via weight loss, GLP-1 receptor agonists likely exert beneficial effects irrespective of weight loss.…”

Section: Clinical Reportsmentioning

confidence: 99%

See 4 more Smart Citations

Glycemic Control in the Treatment of Psoriasis

Ip¹,

Kirchhof

2017

Dermatology

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, thiazolidinediones and biguanides, exert beneficial effects in psoriasis. In this review, we summarize the growing evidence supporting the therapeutic role of hypoglycemic agents in psoriasis and discuss the potential underlying mechanisms. We suggest that dermatologists consider the use of hypoglycemic agents in psoriasis especially in cases with coexisting diabetes and in cases in which immunosuppression is contraindicated. Earlier referral to endocrinology in patients with concomitant diabetes may be appropriate.

show abstract

Section: Clinical Reportsmentioning

confidence: 87%

Section: Clinical Reportsmentioning

confidence: 95%

Section: Clinical Reportsmentioning

confidence: 96%

Section: Clinical Reportsmentioning

confidence: 97%

Section: Clinical Reportsmentioning

confidence: 99%

See 3 more Smart Citations

Glycemic Control in the Treatment of Psoriasis

Ip¹,

Kirchhof

2017

Dermatology

View full text Add to dashboard Cite

show abstract

DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

Shao

et al. 2022

Drug Development Research

View full text Add to dashboard Cite

Studies have shown that the DPP-4 inhibitor was effective in improving skin damage in patients with psoriasis, but the exact mechanism was not known. To investigate the therapeutic effects of linagliptin in mice with type 2 diabetes mellitus (T2DM) with psoriasis and its possible therapeutic mechanisms. A total of 32 db/db mice and 16 db/m mice were randomly divided into six groups: normal group, psoriasis group, diabetes group, diabetes combined with psoriasis group, linagliptin-treated diabetes group, and linagliptin-treated diabetes combined with psoriasis group. The levels of serum fasting blood glucose, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured; the levels of serum FINS were determined by enzyme-linked immunoassay and the insulin resistance index was calculated. Basic parameters of diabetes, Psoriasis Area and Severity Index, histopathology of skin, the expression of interleukin (IL)-17A, IL-23, IL-22, and tumor necrosis factor (TNF)-α, and expression levels of measuring p-ERK, p-MAPK and p-nuclear factor kappa B (NF-κB) in skin tissues were measured. After treatment with linagliptin, insulin resistance, and TC and TG levels were reduced in mice with T2DM and psoriasis (p < .05).Moreover, the degree of epidermal tissue thickening, number of keratinized layers, and inflammatory cell infiltration were also reduced (p < .05), as well as the expression levels of inflammatory factors: TNF-α, IL-1β, IL-17A, IL-23, and p-P38/P38, p-ERK/ERK, p-P65/P65 proteins (p < .05). Linagliptin significantly reduced the extent of skin lesions and skin inflammation. The underlying mechanism of this compound may be related to the inhibition of MAPK/NF-κB inflammatory pathways and the consequential improvement of insulin resistance.Significance Statement: In this study, we evaluated the therapeutic effect of the DPP-4 inhibitor linagliptin using a murine model of type 2 diabetes combined with psoriasis, and its potential mechanisms of action were further explored. The results of this study will help to uncover the pathogenesis of type 2 diabetes and psoriasis and, more importantly, provide a theoretical basis for the search for safe and effective drugs in the treatment of this specific patient population.

show abstract